Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Pen device Clear all
Withdrawn Phase 1 Interventional

Exenatide For Reducing the Reinforcing Effects of Cocaine

NCT06252623
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 8, 2026, 11:15 PM EDT
Recruiting Phase 3 Interventional

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

NCT07533175
View directory record Official record
Conditions
Diabetes Mellitus, Overweight, Obesity
Interventions
NNC0487-0111, Placebo (matched to NNC0487-0111)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Lomita, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

NCT05878938
View directory record Official record
Conditions
Haemophilia A, Haemophilia A With Inhibitors
Interventions
NNC0365-3769 (Mim8) PPX
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
12 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

NCT02320721
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
64
States / cities
Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 8, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Teen Health Choices & Wellness

NCT06822569
View directory record Official record
Conditions
Health Behavior, Wellness, Psychological, Substance Use
Interventions
Cue reactivity paradigm
Other
Lead sponsor
Brown University
Other
Eligibility
13 Years to 16 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Not applicable Interventional

Improving Electronic Written Communication in Aphasia

NCT03773419
View directory record Official record
Conditions
Aphasia
Interventions
Texting Intervention (T-WRITE), HandWriting Intervention (ORLA+WTG)
Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Chicago, Illinois • Harrisonburg, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 8, 2026, 11:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of an Online, Remote Cognitive Battery for Use in Cancer Survivorship

NCT03674437
View directory record Official record
Conditions
Breast Cancer Survivors
Interventions
Traditional Neurocognitive Assessments, Online Cognitive Battery (Cogsuite)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Results available

Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

NCT01226043
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2013 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Imaging Guided Patient Selection for Interventional Revascularization Therapy

NCT00963989
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Penumbra System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis

NCT04064411
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
abaloparatide, abaloparatide solid microstructured transdermal system
Combination Product
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Study of Safety and Efficacy of a rhPTH[1-84] of Fixed Doses of 25 and 50 mcg in Adults With Hypoparathyroidism (RELAY)

NCT01268098
View directory record Official record
Conditions
Hypoparathyroidism
Interventions
NPSP558
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 85 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Lakewood, California • Chicago, Illinois • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Dulaglutide in Healthy Participants

NCT03363906
View directory record Official record
Conditions
Healthy
Interventions
Dulaglutide (Reference), Dulaglutide (Test)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2019 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)

NCT00308139
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, long acting release, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
24
States / cities
Encino, California • La Jolla, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Sep 8, 2026, 11:15 PM EDT
Withdrawn Phase 4 Interventional

Supracondylar Distal Femur Fractures and Abaloparatide

NCT04626141
View directory record Official record
Conditions
Femoral Fractures
Interventions
Abaloparatide, Placebo
Drug
Lead sponsor
Daniel Horwitz
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Sep 8, 2026, 11:15 PM EDT
Not yet recruiting Phase 3 Interventional

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970
View directory record Official record
Conditions
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions
Anifrolumab, Anifrolumab
Combination Product · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
5 Years to 80 Years
Enrollment
1,072 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Los Angeles, California • Fort Lauderdale, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes

NCT01364584
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Sep 8, 2026, 11:15 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight

NCT07525791
View directory record Official record
Conditions
Overweight, Obesity
Interventions
NNC0662-0419, Oral contraceptive, Acetaminophen
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)

NCT03987074
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Semaglutide, Firsocostat, Cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Chandler, Arizona • Coronado, California • La Jolla, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

NCT01147250
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Lixisenatide (AVE0010), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years and older
Enrollment
6,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
200
States / cities
Birmingham, Alabama • Foley, Alabama • Mobile, Alabama + 160 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family-Authored ICU Diaries to Reduce Fear in Patients Experiencing a Cardiac Arrest (FAID Fear)

NCT05144477
View directory record Official record
Conditions
Cardiac Arrest, Post Traumatic Stress Syndrome
Interventions
FAID Fear Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Not applicable Interventional Results available

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

NCT03876457
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

NCT01476475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 8, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 8, 2026, 11:15 PM EDT
Recruiting Not applicable Interventional

Treatment Validation for Myofascial Pain

NCT07133139
View directory record Official record
Conditions
Chronic Low-back Pain (cLBP), Myofacial Pain
Interventions
Dry Needling, Sham Dry Needling, NUN Biomarker
Device · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
20 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 8, 2026, 11:15 PM EDT